[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
Bayer: Weedkiller maker to take $2.8bn hit as sales fall
In all, it has set aside over $15bn (£11.7bn) to settle lawsuits alleging its herbicides are linked to non-Hodgkin's lymphoma and other cancers. On Monday, the Leverkusen-based company said it expected a net loss of €2bn in the three months to the end of June. The firm also forecast that its…#nonhodgkin #leverkusen #bayer #monsanto #roundup #wernerbaumann (Source: Reuters: Health)
Source: Reuters: Health - July 25, 2023 Category: Consumer Health News Source Type: news
Aurobindo Pharma arm gets USFDA nod for Plerixafor injection
Aurobindo Pharma said Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 25, 2023 Category: Pharmaceuticals Source Type: news
Anti-PD-1 Alone Produces Durable Responses in Relapsed/Refractory PMBCL
(MedPage Today) -- Credit: CoRus13
Single-agent pembrolizumab (Keytruda) produced durable responses and encouraging survival in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL), according to long-term follow... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 24, 2023 Category: Hematology Source Type: news
All-Star pitcher Liam Hendriks shares how he closed out cancer at Mayo Clinic in Arizona
Bigger than baseball That's how some describe Liam Hendriks' battle against cancer. At 33 years old, the All-Star Major League Baseball closing pitcher is a fan favorite and famous for throwing fastballs at blazing speeds. But, at only 33 years old, at the end of the 2022 MLB season, Hendriks made the sobering announcement - he had been diagnosed with stage 4 non-Hodgkin's lymphoma. The day after that announcement, Hendriks began cancer treatment at Mayo… (Source: Mayo Clinic Arizona News)
Source: Mayo Clinic Arizona News - July 21, 2023 Category: Hospital Management Source Type: news
Tony Iommi's four-year battle with non-Hodgkin lymphoma - first sign
The legendary rocker has previously said the disease will "probably" come back. (Source: Daily Express - Health)
Source: Daily Express - Health - July 20, 2023 Category: Consumer Health News Source Type: news
New Trials in Leukemia and Lymphoma Enrolling Now New Trials in Leukemia and Lymphoma Enrolling Now
Could one of your patients benefit from clinical trials now looking for patients with leukemia or lymphoma?Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - July 18, 2023 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
Between hope and despair: Improving cancer outcomes
I can still see everything in the hospital room in my mind ’s eye, the night — 13 days before Christmas — a neurologist delivered the news to my mother and me that she had non-Hodgkin’s lymphoma, an aggressive tumor lodged in her brain. It threw our little family into a panic and into a search for the best treatment available in the subsequent 8 mon ths before her death. Unfortunately, the tumor was diagnosed late in progression and inoperable. In 2009, there weren’t many treatment options available, and the doctors weren’t sure how to respond because not many Black patients had had similar diagnoses, so there ...
Source: The Catalyst - July 11, 2023 Category: Pharmaceuticals Authors: Courtney Christian Tags: Cancer Health Equity Source Type: news
Episode 4: CAR T-Cell Therapy for B-Cell Lymphomas Episode 4: CAR T-Cell Therapy for B-Cell Lymphomas
Join Drs Amelia Langston and Loretta Nastoupil as they discuss current CAR T-cell therapy for B-cell lymphomas as leading researchers and practitioners in the field.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 11, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
European Commission approves Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and treatment-free periodBasel, 11 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) ha...
Source: Roche Media News - July 11, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and treatment-free periodBasel, 11 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) ha...
Source: Roche Investor Update - July 11, 2023 Category: Pharmaceuticals Source Type: news
Progression of Hodgkin Lymphoma and Plasma Cell Neoplasms Progression of Hodgkin Lymphoma and Plasma Cell Neoplasms
This case-based report reviews the clinical presentation, morphologic, and molecular findings in 20 cases of Hodgkin lymphoma and plasma cell neoplasms and their subsequent progression.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 6, 2023 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
(MedPage Today) -- The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) demonstrated promising efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 5, 2023 Category: Hematology Source Type: news
Key Data in Non-Hodgkin Lymphoma From EHA 2023 Key Data in Non-Hodgkin Lymphoma From EHA 2023
Key data in non-Hodgkin lymphoma from EHA 2023 include evidence for omitting radiotherapy, findings of no benefit of IV over IT methotrexate in CNS prophylaxis, and two positive CAR T-cell studies.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
